Melinta Therapeutics' Phase 3 Study of I.V. and Oral Delafloxacin has Begun Enrolling Patients with Acute Bacterial Skin and Skin Structure Infections
May 05, 2014 11:27 ET
|
Melinta Therapeutics
NEW HAVEN, Conn, May 5, 2014 (GLOBE NEWSWIRE) -- Melinta Therapeutics today
announced that patient enrollment has commenced in a Phase 3 trial
of oral and intravenous (I.V.) delafloxacin, a...
Melinta Therapeutics to Present at Needham & Company's Annual Healthcare Conference
April 03, 2014 14:38 ET
|
Melinta Therapeutics
NEW HAVEN, Conn, April 3, 2014 (GLOBE NEWSWIRE) -- Melinta Therapeutics
today announced that Mary Szela, the Company's chief executive
officer, will be presenting a corporate update at Needham...
Melinta Therapeutics Raises $70 Million to Support Delafloxacin NDA and Selection of Multi-Drug Resistant Gram-Negative Candidates from RX-04 Platform
February 10, 2014 07:30 ET
|
Melinta Therapeutics
NEW HAVEN, Conn, Feb. 10, 2014 (GLOBE NEWSWIRE) -- Melinta Therapeutics today
announced the closing of a $70 Million Series 3 equity
financing. Current investor, Vatera Healthcare Partners,...
Melinta Therapeutics Initiates Phase 3 Registration Study of Delafloxacin in Individuals with Uncomplicated Gonorrhea
January 09, 2014 08:00 ET
|
Melinta Therapeutics
NEW HAVEN, Conn, Jan. 9, 2014 (GLOBE NEWSWIRE) -- Melinta Therapeutics
today announced the initiation of a Phase 3 trial of delafloxacin,
a novel investigational fluoroquinolone, for the...
Melinta Therapeutics to Present at J.P. Morgan Healthcare Conference
January 09, 2014 08:00 ET
|
Melinta Therapeutics
NEW HAVEN, Conn, Jan. 9, 2014 (GLOBE NEWSWIRE) -- Melinta Therapeutics
today announced that Mary Szela, the Company's chief executive
officer, will be providing a corporate and clinical update...
Melinta Therapeutics Bolsters Executive Team with Appointment of Paul Estrem as Chief Financial Officer
December 02, 2013 08:00 ET
|
Melinta Therapeutics
NEW HAVEN, Conn, Dec. 2, 2013 (GLOBE NEWSWIRE) -- Melinta Therapeutics today
announced the appointment of Paul Estrem to the role of chief
financial officer. Mr. Estrem brings more than 20 years...
Melinta Therapeutics Prepares for Late-Stage Product Launches with Appointment of Sue Cammarata, M.D. as Chief Medical Officer
November 19, 2013 08:00 ET
|
Melinta Therapeutics
NEW HAVEN, Conn, Nov. 19, 2013 (GLOBE NEWSWIRE) -- Melinta Therapeutics today announced the appointment of Sue
Cammarata, M.D. as chief medical officer. In this role, Dr.
Cammarata will be...
Cran-Max Effective Prevention in High Risk Cases of UTI
October 23, 2013 15:21 ET
|
Cran-Max
KEARNY, NJ--(Marketwired - Oct 23, 2013) - Urinary tract infections (UTI) are responsible for more than 7 million doctor visits a year. Although UTIs can be treated in the short term with...
Melinta Therapeutics Expands Leadership Team with Appointment of Lyn Baranowski as SVP of Corporate Development and Strategy
October 07, 2013 10:00 ET
|
Melinta Therapeutics
NEW HAVEN, Conn, Oct. 7, 2013 (GLOBE NEWSWIRE) -- Melinta Therapeutics today announced the appointment of Lyn
Baranowski as senior vice president, corporate development and
strategy. In this...
Fedora Pharmaceuticals Demonstrates that FPI-1465 Increases Activity of Certain Antibiotics against Drug-Resistant Bacteria
September 12, 2013 13:00 ET
|
Fedora Pharmaceuticals, Inc.
EDMONTON, Alberta, Sept. 12, 2013 (GLOBE NEWSWIRE) -- Fedora Pharmaceuticals, Inc. and its collaborators presented
results of preclinical studies demonstrating that FPI-1465 increases
the activity of...